Collegium Pharmaceutical (COLL) Total Debt (2014 - 2026)

Collegium Pharmaceutical's Total Debt history runs 13 years deep, the most recent figure standing at $564.3 million for Q1 2026.

• In Q1 2026, Total Debt fell 5.99% year-over-year to $564.3 million; the TTM figure through Mar 2026 stood at $564.3 million (down 5.99% YoY), while the FY2025 annual figure was $571.1 million, down 7.18% from the prior year.
• Total Debt was $564.3 million for Q1 2026 at Collegium Pharmaceutical, down from $571.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $630.3 million in Q3 2024 to a low of $316.2 million in Q2 2024.
• Historically, Total Debt has averaged $526.2 million across 5 years, with a median of $560.1 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Total Debt surged 409.07% in 2022, then plunged 35.9% in 2024.
• A 5-year view of Total Debt shows it stood at $560.1 million in 2022, then decreased by 27.68% to $405.0 million in 2023, then soared by 51.91% to $615.3 million in 2024, then declined by 7.18% to $571.1 million in 2025, then fell by 1.18% to $564.3 million in 2026.
• The last three Total Debt figures came in at $564.3 million (Q1 2026), $571.1 million (Q4 2025), and $505.6 million (Q3 2025), per Business Quant data.